12 Month Price Forecast For GHRS
Distance to GHRS Price Forecasts
GHRS Price Momentum
🤔 Considering GH Research (GHRS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 16, 2025 3:37 AM UTC
GHRS Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, GHRS has a bullish consensus with a median price target of $37.00 (ranging from $18.00 to $40.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $14.31, the median forecast implies a 158.6% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 179.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GHRS Analyst Consensus
GHRS Price Target Range
Latest GHRS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GHRS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 13, 2025 | Cantor Fitzgerald | Charles Duncan | Overweight | Initiates | $14.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Jan 13, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Nov 18, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $28.00 |
| Sep 5, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Sep 4, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $39.00 |
| Jul 31, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| May 7, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| May 6, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $31.00 |
| Mar 4, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Mar 1, 2024 | JMP Securities | Jason Butler | Market Outperform | Maintains | $39.00 |
| Jan 18, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $40.00 |
| Dec 18, 2023 | Stifel | Buy | Maintains | $0.00 | |
| Nov 14, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $40.00 |
| Jul 6, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $45.00 |
| May 12, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $45.00 |
| May 12, 2023 | JMP Securities | Jason Butler | Outperform | Maintains | $49.00 |
| Mar 13, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $45.00 |
Stocks Similar to GH Research plc
The following stocks are similar to GH Research based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GH Research plc (GHRS) Financial Data
GH Research plc has a market capitalization of $887.62M with a P/E ratio of -21.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -20.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
GH Research plc (GHRS) Company Overview
About GH Research plc
Develops therapies for psychiatric and neurological disorders.
The company focuses on developing innovative therapies, specifically 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), targeting treatment-resistant depression and other psychiatric conditions. It generates revenue through the advancement of its clinical programs, with multiple candidates in various phases of clinical trials, aiming for successful treatments that can be commercialized.
Founded in 2018 and based in Dublin, Ireland, GH Research PLC is actively pursuing clinical trials for its product candidates, including inhalable, intravenous, and intranasal formulations. The company is well-positioned in a growing market for mental health therapies, especially for patients who have not responded to traditional treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
49
CEO
Dr. Theis Terwey M.D.
Country
Ireland
IPO Year
2021
Website
www.ghres.comGH Research plc (GHRS) Latest News & Analysis
GH Research's stock rose 55% in a week following the successful achievement of the primary goal in a mid-stage depression study for its lead candidate, GH001.
GH Research's stock surge reflects positive sentiment and potential for future growth, indicating strong investor confidence in its lead candidate's prospects.
GH Research PLC announced that its Phase 2b trial for GH001, an inhalable bufotenin candidate for treatment-resistant depression, successfully met its primary endpoint.
GH Research's successful Phase 2b trial for GH001 boosts confidence in its potential market approval, likely leading to increased stock value and investor interest in treatment-resistant depression therapies.
GH Research PLC (Nasdaq: GHRS) reported positive results from a Phase 2b trial of GH001 for treatment-resistant depression, meeting its primary endpoint. A conference call is scheduled for today at 8 a.m. EST.
Positive trial results for GH001 in treatment-resistant depression may boost GH Research PLC's stock, signaling potential market approval and increased revenue prospects.
GH Research Announces Proposed Public Offering
12 days agoGH Research PLC (Nasdaq: GHRS) has launched a $150 million underwritten public offering of ordinary shares, with an option for underwriters to purchase an additional $22.5 million.
GH Research PLC's $150 million public offering indicates a need for capital, potentially affecting share price and investor confidence amid market conditions.
GH Research PLC has priced a public offering of 10 million shares at $15 each, raising approximately $150 million. The offering closes on February 6, 2025, with a 30-day option for underwriters to buy 1.5 million more shares.
The $150 million capital raise indicates GH Research's commitment to funding its depression treatment development, potentially impacting its stock valuation and investor confidence.
GH Research PLC (Nasdaq: GHRS) will host a conference call on February 3, 2025, at 8:00 a.m. EST to discuss data from its Phase 2b trial of GH001 for treatment-resistant depression.
The upcoming conference call on GH001's Phase 2b trial results could influence GH Research PLC's stock price and investor sentiment in the biopharmaceutical sector, particularly for psychiatric treatments.
Frequently Asked Questions About GHRS Stock
What is GH Research plc's (GHRS) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, GH Research plc (GHRS) has a median price target of $37.00. The highest price target is $40.00 and the lowest is $18.00.
Is GHRS stock a good investment in 2025?
According to current analyst ratings, GHRS has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.31. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for GHRS stock?
Wall Street analysts predict GHRS stock could reach $37.00 in the next 12 months. This represents a 158.6% increase from the current price of $14.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is GH Research plc's business model?
The company focuses on developing innovative therapies, specifically 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), targeting treatment-resistant depression and other psychiatric conditions. It generates revenue through the advancement of its clinical programs, with multiple candidates in various phases of clinical trials, aiming for successful treatments that can be commercialized.
What is the highest forecasted price for GHRS GH Research plc?
The highest price target for GHRS is $40.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 179.5% increase from the current price of $14.31.
What is the lowest forecasted price for GHRS GH Research plc?
The lowest price target for GHRS is $18.00 from at , which represents a 25.8% increase from the current price of $14.31.
What is the overall GHRS consensus from analysts for GH Research plc?
The overall analyst consensus for GHRS is bullish. Out of 6 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $37.00.
How accurate are GHRS stock price projections?
Stock price projections, including those for GH Research plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
